Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02389075
Recruitment Status : Enrolling by invitation
First Posted : March 17, 2015
Last Update Posted : October 4, 2019
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This study plans to learn more about the relationship between systemic autoimmune disease, such as inflammatory bowel disease and ankylosing spondyloarthritis, bacteria in the colon, and the changes in colon tissue.

Condition or disease Intervention/treatment
Inflammatory Bowel Diseases (IBD) Ankylosing Spondylitis (AS) Procedure: Pinch biopsies Procedure: Flexible sigmoidoscopy

Detailed Description:
Changes in human gut bacteria has been shown in patients with autoimmune diseases, such as inflammatory bowel diseases (IBD). The gut flora in ankylosing spondylitis (AS), an arthritis that can occur with IBD, has not been well studied. The immune cells in the colon directly interface with bacteria and may be influenced by them. The interactions between the colon immune system, bacteria and autoimmunity hasn't been studied. The study goal is to specifically study the link between bacteria, the colonic immune system, and the autoimmune diseases of AS and IBD. This will be done by collecting clinical data by questionnaires, blood samples, colonic tissue during endoscopy, and microbiome data in subjects with IBD, AS, and controls.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis
Study Start Date : March 2015
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Ankylosing Spondylitis
Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
Procedure: Pinch biopsies
Biopsies obtained during colonoscopy or flexible sigmoidoscopy.

Procedure: Flexible sigmoidoscopy
Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy

Inflammatory Bowel Disease
Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
Procedure: Pinch biopsies
Biopsies obtained during colonoscopy or flexible sigmoidoscopy.

Healthy Controls
Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
Procedure: Pinch biopsies
Biopsies obtained during colonoscopy or flexible sigmoidoscopy.




Primary Outcome Measures :
  1. IEL characteristics in IBD, AS, and healthy controls [ Time Frame: 1 hour after colonoscopy ]
    The primary goal for this measure will be to demonstrate characteristics of IEL (intraepithelial lymphocytes) subtypes of healthy individuals and compare those with AS or IBD. IEL characteristics will be based on cell marker outcomes using flow cytometry for CD3, CD4, CD8α, CD8β, CD44, CD45, CD62L, CD69, CD103, TCRαβ, and TCRγδ.


Secondary Outcome Measures :
  1. Microbiome Differences in IBD, AS, and healthy controls [ Time Frame: 1 hour after colonoscopy ]
    The primary hypothesis is that the microbiome population will differ between controls, IBD, and AS; outcomes for this hypothesis will include relative abundance (RA) of individual bacterial species and the Shannon Index for community diversity.

  2. Microbiome changes are reflected in IELs [ Time Frame: 1 hour after colonoscopy ]
    The primary hypothesis is that dysbiosis will be reflected in the IEL populations in AS and IBD by having a different predominant phenotype (as seen by cell markers) compared to healthy controls; the investigators will evaluate the IEL outcomes determined to be significantly different among AS, IBD, and healthy controls as identified in Outcome 1 (Primary Outcome).


Biospecimen Retention:   Samples With DNA
Colon pinch biopsies, white blood cells.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Inflammatory Bowel Disease, Ankylosing Spondylitis, and Healthy Controls
Criteria

Healthy Controls

Exclusion criteria:

  • Pregnancy
  • Use of antibiotics within the past 14 days†
  • Current diagnosis of colon cancer
  • Diagnosis of celiac disease
  • Diagnosis of any other rheumatologic disease such as RA, SLE, etc.
  • Chemotherapy or radiation therapy for any malignancy within the past year
  • Daily use of aspirin or NSAIDs with inability to hold the drug 7 days before and after the procedure
  • Current use of anticoagulation (LMWH,warfarin,etc.)
  • A diagnosis of HIV
  • Clostridium difficile within the past 3 months

IBD

Inclusion Criteria:

  • Established IBD (either Crohn's disease or ulcerative colitis)
  • Suspected to have IBD by a gastroenterologist and undergoing diagnostic endoscopy and biopsy. Diagnosis will be confirmed on biopsy and patients who are negative will be considered for controls based on the pathology found.

Exclusion Criteria:

  • Pregnancy
  • Use of antibiotics within the past 14 days
  • Current diagnosis of colon cancer
  • Diagnosis of celiac disease
  • Diagnosis of any other rheumatologic disease such as RA, SLE, etc.
  • Chemotherapy or radiation therapy for any malignancy within the past year
  • Daily use of aspirin or NSAIDs with inability to hold the drug 7 days before and after the procedure
  • Current use of anticoagulation (LMWH, warfarin,etc.)
  • A diagnosis of HIV
  • Clostridium difficile within the past 3 months
  • Evidence of inflammatory spinal or axial arthritis or disease based on chart review such as inflammation seen on radiographs or a diagnosis of sacroiliitis

AS:

Inclusion Criteria:

  • Diagnosed with an axial spondyloarthritis (SpA) by a rheumatologist -
  • Meet the Assessment of SpondyloArthritis international Society (ASAS) axial spondyloarthritis (SpA) criteria

Exclusion criteria:

  • Pregnancy
  • Use of antibiotics within the past 14 days
  • Current diagnosis of colon cancer
  • Diagnosis of celiac disease
  • Diagnosis of any other rheumatologic disease such as RA, SLE, etc.
  • Chemotherapy or radiation therapy for any malignancy within the past year
  • Daily use of aspirin or NSAIDs with inability to hold the drug 7 days before and after the procedure
  • Current use of anticoagulation (LMWH,warfarin,etc.)
  • A diagnosis of HIV
  • Clostridium dificile within the past 3 months
  • A known history of idiopathic macroscopic or microscopic colitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02389075


Locations
Layout table for location information
United States, Colorado
Denver, Colorado, United States
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Kristie Kuhn, MD, PhD University of Colorado, Denver

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02389075     History of Changes
Other Study ID Numbers: 14-1507
UL1TR001082 ( U.S. NIH Grant/Contract )
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: October 4, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Colorado, Denver:
intraepithelial lymphocytes (IEL)
microbiome
colon mucosa
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis